関連ニュース

BioStem Technologies OTCMKTS: BSEM outlined its strategy to expand in surgical applications, shift its revenue mix away from physician-office wound care and bring manufacturing of acquired products in

BioStem Technologies OTCMKTS: BSEM reported second-quarter revenue of $7.9 million as the company continued its transition to a predominantly hospital-focused commercial model. Revenue increased from

POMPANO BEACH, Fla., July 10, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufactu